Healthy Adult Volunteers Clinical Trial
— MIHMoSAOfficial title:
Metabolism of Isotonic Versus Hypotonic Maintenance Solutions in Fasting Healthy Adults, a Single-Blind Randomized Crossover Trial
The prescription of intravenous maintenance solutions - although widespread - lacks important data on the optimal sodium and potassium content, which has given rise to an important debate in the scientific literature. Our study compares two different infusion fluids in 12 healthy adult volunteers without renal failure in a single-blind randomized crossover design over two 48 hour periods during which subjects are not allowed to eat or drink. Fluid 1 is a premixed solution containing 54 mmol/L of sodium and 26 mmol/L of potassium; fluid 2 is sodium chloride 0.9% in glucose 5% with 40 mmol/L of potassium. Both solutions are administered at 25 mL/kg of ideal body weight, as recommended by current guidelines (NICE 174) and both solutions are widely used in daily clinical practice. The primary hypothesis is that isotonic maintenance solutions lead to more fluid retention than hypotonic fluids. Metabolism of both solutions is assessed by sequential analysis of urine and serum, clinical parameters and bioelectrical impedance analysis.
Status | Completed |
Enrollment | 12 |
Est. completion date | August 2016 |
Est. primary completion date | August 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Healthy adults, 18-70 years of age - BMI 17-45 kg/m². - Creatinine clearance >60 ml/min (according to eGFR CKD-EPI formula). Exclusion Criteria: - Acute medical illness within 3 weeks of first study period - Chronic medication: under diuretic therapy or other chronic medication that interfere with urine output or induce urine retention. All chronic medication should be declared before being enrolled in the study. - Medical history: - cardiac failure, - malnourishment, - diabetes mellitus, - urological disease preventing spontaneous or complete emptying of the bladder, - any medical or non-medical issue preventing complaint-free fasting for 48 hours (e.g. active peptic ulcer, psychosis, substance abuse…) - Pregnancy |
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
Belgium | University Hospital, Antwerp | Edegem |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Antwerp | Baxter Healthcare Corporation |
Belgium,
Lobo DN, Bostock KA, Neal KR, Perkins AC, Rowlands BJ, Allison SP. Effect of salt and water balance on recovery of gastrointestinal function after elective colonic resection: a randomised controlled trial. Lancet. 2002 May 25;359(9320):1812-8. — View Citation
Moritz ML, Ayus JC. Maintenance Intravenous Fluids in Acutely Ill Patients. N Engl J Med. 2015 Oct;373(14):1350-60. doi: 10.1056/NEJMra1412877. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Osmoregulatory Profile 1: urinary volume (mL) | Sequential changes in mean urinary volume (per fluid type) at T0-T12-T24-T36-T48. | 48h | No |
Other | Osmoregulatory Profile 2: urinary osmolality (mOsm/kg) | Sequential changes in mean urinary osmolality (per fluid type). Urinary osmolality is determined on a sample of every individual diuresis. Subjects urinate as the urge rises. | 48h | No |
Other | Osmoregulatory Profile 3: serum antidiuretic hormone (ADH) (pg/mL) | Sequential changes in mean serum ADH (per fluid type) at T0-T24-T48. | 48h | No |
Other | Osmoregulatory Profile 4: thirst score (scale 0-5) | Sequential changes in mean thirst score (per fluid type) at T0-T12-T24-T36-T48. The thirst score is a subjective score on a scale of 0-5. | 48h | No |
Other | Volume Regulatory Profile 1: urinary sodium (mmol/L) | Sequential changes in mean urinary sodium (per fluid type). Urinary sodium is determined on a sample of every individual diuresis. Subjects urinate as the urge rises. Urinary sodium is used to calculate the fractional excretion of sodium. | 48h | No |
Other | Volume Regulatory Profile 2: serum aldosterone (ng/dL) | Sequential changes in mean serum aldosterone (per fluid type) at T0-T24-T48. | 48h | No |
Other | Volume Regulatory Profile 3: urinary potassium (mmol/L) | Sequential changes in mean urinary potassium (per fluid type). Urinary potassium is determined on a sample of every individual diuresis. Subjects urinate as the urge rises. | 48h | No |
Other | Acid-Base Profile 1: serum chloride (mmol/L) | Sequential changes in mean serum chloride (per fluid type) at T0-T12-T24-T36-T48. | 48h | No |
Other | Acid-Base Profile 2: serum apparent strong ion difference (mEq/L) | Sequential changes in mean serum apparent strong ion difference (per fluid type) at T0-T12-T24-T36-T48. | 48h | No |
Other | Acid-Base Profile 3: urinary anion gap (mmol/L) | Sequential changes in mean urinary anion gap (per fluid type). Urinary potassium is determined on a sample of every individual diuresis. Subjects urinate as the urge rises. | 48h | No |
Other | Other Electrolytes Profile 1: Serum phosphate (mmol/L) | Sequential changes in mean serum phosphate (per fluid type) at T0-T24-T48. | 48h | No |
Other | Other Electrolytes Profile 2: Red blood cell magnesium (mmol/L) | Sequential changes in mean red blood cell magnesium (per fluid type) at T0-T24-T48. | 48h | No |
Other | Cortisol (µg/dL) | Serum cortisol as a measure of stress due to fasting. | 48h | No |
Other | Bioelectrical impedance analysis 1: Total body water | Sequential changes in mean total body water (per fluid type) at T0-T24-T48. | 48h | No |
Other | Bioelectrical impedance analysis : Extracellular volume | Sequential changes in mean extracellular volume (per fluid type) at T0-T24-T48. | 48h | No |
Primary | Urine Output | Urinary output over study period (as AUC). | 48h | No |
Primary | Body weight | Body weight over study period (as AUC), used as a back up parameter for urinary output. | 48h | No |
Secondary | Amount of sodium retention / excretion (excreted sodium / administered sodium) | Sodium retention / excretion over study period (mean at 24 and 48h) | 48h | No |
Secondary | Number of episodes of hypokalemia (<3.5 mmol/L), hyponatremia (<135 mmol/L), hypernatremia (>145 mmol/L) | 48h | Yes | |
Secondary | Change of sodium level from its baseline value. | Area under the electrolyte concentration curve (baseline level is reference line) | 48h | No |
Secondary | Change of sodium and potassium level from its baseline value. | Area under the electrolyte concentration curve (baseline level is reference line) | 48h | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06034899 -
A Study to Evaluate the Effect of Food on the Drug Levels of BMS-986196 in Healthy Adult Participants
|
Phase 1 | |
Completed |
NCT05162274 -
Clinical Trial to Assess Bioequivalence of Lazertinib Between Two Formulations in Healthy Volunteers.
|
Phase 1 | |
Completed |
NCT03748758 -
Evaluation of Safety of Repeated Doses of OP0201 Metered Dose Inhaler Compared to Placebo in Healthy Adult Volunteers
|
Phase 1 | |
Recruiting |
NCT06008652 -
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DR-0201 in Healthy Adult Volunteers
|
Phase 1 | |
Terminated |
NCT02079480 -
Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01651325 -
Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Dextromethorphan in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT01657838 -
Drug Interaction Study of the Effect of Ketoconazole at Steady State on the Pharmacokinetics of a Single Dose of Isavuconazole in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT01354379 -
Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008 Administered by Sprayer
|
Phase 1 | |
Completed |
NCT01129466 -
Effects of 2 Different Broccoli Sprout Containing Supplements on Nasal Cells in Healthy Volunteers
|
N/A | |
Completed |
NCT04856969 -
Clinical Trial to Evaluate Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers
|
Phase 1 | |
Completed |
NCT01333462 -
Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008
|
Phase 1 | |
Completed |
NCT02942771 -
A MAD Study of TT301/MW189 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05017987 -
Clinical Trial to Compare Pharmacokinetics After Administration of ATB-101 or Co-administration of ATB-1011 and ATB-1012
|
Phase 1 | |
Not yet recruiting |
NCT05757596 -
Study of VSA001 Injection in Chinese Healthy Adult Volunteers
|
Phase 1 | |
Completed |
NCT05074368 -
Efficacy and Safety of Heterologous and Homologous COVID-19 Vaccination
|
N/A | |
Completed |
NCT01672242 -
Assessment of End Expiratory Lung Volumes in Healthy Subjects Using High Flow Oxygen (Vapotherm®)
|
N/A | |
Completed |
NCT03878693 -
4-methylpyrazole and Acetaminophen Metabolism
|
Early Phase 1 | |
Completed |
NCT04204772 -
A Pilot Feasibility Study of Activated Charcoal in Healthy Volunteers
|
Early Phase 1 | |
Completed |
NCT05154461 -
Intestinal Ketone Bodies Interfere With the Glycemic Control
|
N/A | |
Active, not recruiting |
NCT02058472 -
Pharmacokinetic/Pharmacodynamic & Safety Study of G3041 and SEVIKAR® Tablet in Healthy Adult Volunteers
|
Phase 1 |